Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/df00a65e-5367-422f-97a6-b0f2eecc593e/

LXRX

Lexicon Pharmaceuticals Inc
Chart
$1.91
Latest Week 2026-06-05
HealthcareBiotechnologySMALL
Snapshot 2026-06-07 · 0.0w · Fresh
0.25
OS Score
23.0%
Value
7.0%
Quality
95.0%
Momentum
4/9
F-Score
0.127
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
1 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
RAM 2.08
V
Value Analysis
Cheapness relative to fundamentals
23.0%ile
P/S
11.0×
P/B
3.8×
FCF Yield
-0.050
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
80.00000000
/100 — 1=cheapest
VC2 (Trending Value)
82.00000000
/100
VC3 (Buyback)
82.00000000
/100
Negative FCF yield (-5.0%) — the business is currently cash-consumptive. VC2 score of 82.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
7.0%ile
ROE
-0.129
ROA
-0.097
Net Margin
-0.375
Op Margin
-0.299
GPA
0.257
D/E
0.33
Current
18.79
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
1.231
Stability
0.950
lower=better
Accruals
0.047
lower=better
5yr Consist
No
Conservative balance sheet with D/E of 0.33.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
95.0%ile
6M Return
36.4%
12M Return
149.1%
12-1 Mom
160.9%
Risk-Adj
2.08
Vol 252d
77.5%
Vol 60d
177.7%
↑ Expanding
Max DD 12M
-31.8%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 161% is very strong — a clear uptrend. Risk-adjusted momentum of 2.08 is excellent — strong returns relative to volatility. Near-term vol (178%) is expanding vs long-term (78%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.25
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
6.8%
Sector Quality %ile
2.2%
P/B z-score
-0.10
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Hot but Volatile
Strong momentum (95th) but high volatility (78%). Momentum could reverse sharply.
Volatility Expanding
60-day vol (178%) significantly exceeds 252-day (78%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
23.7% avg (4 factors)
Quality
D
35.5% avg (8 factors)
Momentum
A
90.0% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.250—1—
Value %ile0.230—1—
Quality %ile0.070—1—
Momentum %ile0.950—1—
F-Score4.000—1—
Confidence0.848—1—
Volatility0.775—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
10.98
Price / Book
3.77
FCF Yield
-5.0%
Sales Yield (1/P·S)
0.0896
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-12.9%
Return on Assets
-9.7%
Net Margin
-37.5%
Operating Margin
-29.9%
Gross Profit / Assets
Novy-Marx GPA
25.7%
Debt / Equity
0.33
Current Ratio
18.79
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.047
MomentumPrice trend strength over different horizons
6M Return
36.4%
12M Return
149.1%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
160.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
2.08
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
123.1%
Earnings Stability (CV)
Lower = more stable
0.950
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
80
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
82
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
82
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity